Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
kANMLmyCYYcJ9Ca7
